Merck KGaA, Darmstadt, Germany

In February 2024, C4 Therapeutics and Merck KGaA, Darmstadt, Germany, which operates its healthcare business as EMD Serono in the U.S. and Canada, announced a strategic discovery research collaboration against critical oncogenic proteins. Under the terms of the agreement, C4T and Merck KGaA, Darmstadt, Germany will collaborate to discover two targeted protein degraders against critical oncogenic proteins that C4T has progressed within its internal pipeline. C4T will be responsible for utilizing its proprietary TORPEDO^® platform to discover degraders targeting the partnership’s oncogenic proteins of interest. Merck KGaA, Darmstadt, Germany, will be responsible for clinical development and commercialization for drug candidates coming out of these programs.